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Muriel Cario-Andre´,1,2 Ve´ronique Guyonnet-Dupe´rat,1,2 Laurence Taine,1,2 Ce´cile Ged,1,2
and Hubert de Verneuil1,2,*
Achieving long-term expression of a therapeutic gene in a given hematopoietic lineage remains an important goal of gene therapy.
Congenital erythropoietic porphyria (CEP) is a severe autosomal-recessive disorder characterized by a deﬁciency in uroporphyrinogen
III synthase (UROS), the fourth enzyme of the heme biosynthetic pathway. We used a recently obtained murine model to check the fea-
sibility of gene therapy in this disease. Lentivirus-mediated transfer of the humanUROS cDNA into hematopoietic stem cells (HSCs) from
Urosmut248 mice resulted in a complete and long-term enzymatic, metabolic, and phenotypic correction of the disease, favored by a
survival advantage of corrected red blood cells. These results demonstrate that the cure of this mouse model of CEP at a moderate trans-
duction level supports the proof of concept of a gene therapy in this disease by transplantation of genetically modiﬁed hematopoietic
stem cells.Introduction
Congenital erythropoietic porphyria (CEP [MIM 263700]),
or Gu¨nther’s disease, is a rare disease that is inherited as an
autosomal-recessive trait and is characterized by severe
cutaneous photosensitivity with mutilating involvement
and chronic hemolysis.1,2 The profound uroporphyrino-
gen III synthase (UROS; EC 4.2.1.75) deﬁciency3 leads to
massive excretion of type I isomers of porphyrins, an
excretion that results from excessive synthesis of these
compounds in the bone marrow. Mutation analysis has
shown a large variety of molecular lesions and has pro-
vided genotype/phenotype correlations to predict the
severity of the clinical evolution of the disease.4–7 The clin-
ical severity of the anemia and cutaneous lesions is highly
variable, and, for some patients, prognosis is poor, with
death in early adult life or in the neonatal period.8,9 Clas-
sical treatments are only symptomatic and unsatisfactory.
Because the predominant site of metabolic expression of
the disease is the erythropoietic system, bone marrow
(BM) transplantation represents a curative treatment for
patients with severe phenotypes, as long as a human leuco-
cyte antigen (HLA)-compatible donor is available.10–19
However, in the absence of HLA-compatible donors, gene
therapy with hematopoietic stem cells (HSCs) is a promis-
ing curative treatment.
Therapeutic trials targeting hematopoietic cells have
been initiated for a number of monogenic diseases, includ-
ing severe combined immunodeﬁciency diseases due to
common g chain (SCID-X1)20,21 ([MIM 300400]) or aden-
osine deaminase (SCID-ADA)22–26 ([MIM 102700]) deﬁ-
ciencies, Gaucher disease27 ([MIM 230800]), and chronic
granulomatous disease (CGD)28,29 ([MIM 306400]). In gen-The Aeral, themain problem resides in the low percentage of cor-
rected cells in peripheral blood several months following
the treatment. One exception is the setting in which a se-
lective advantage is conferred to the corrected target cell.
This is the case for SCID-X1, which was the ﬁrst success
of gene therapy with full correction of disease phenotype
and clinical beneﬁt, and also for SCID-ADA and CGD. In
CGD, a recent clinical trial using retroviral vectors showed
signiﬁcant clinical beneﬁt, owing to an unexpected expan-
sion in vivo of gene-transduced cells by insertional activa-
tion of MDS1-EVI1, PRDM16, or SETBP1.29 A recent mu-
rine model of CEP30 allowed us to test this approach in
this disease. Homozygous Urosmut248/mut248 mice (hereafter
called CEP mice) closely mimic the symptoms observed in
the human disease. Here, we report a complete enzymatic,
metabolic, and phenotypic correction of CEP mice after
HSC gene transfer. Moreover, we demonstrate a survival
advantage of corrected red blood cells. Thus, our results
strongly support the use of HSC gene therapy in clinical
trials for CEP patients.
Material and Methods
Construction and Production of Lentiviral Vectors
Vectors were generated from a self-inactivating (SIN) lentiviral
vector. The EFpGFP and MNDpGFP vectors derived from the
pRRL-PGK-GFP-WPRE lentiviral-vector backbone kindly provided
by Dr. D. Trono were previously described.31 ESpUROS vector was
derived from EFpGFP by replacement of GFP with the human
UROS cDNAandEFpby the chimericHS40/Ankp.32Cloningdetails
are available upon request. VSV-G-pseudotyped lentiviral vectors
were produced by triple-transient transfection of 293T cells as pre-
viously described.33 HIV-1 p24 antigen levels weremeasured in the1Inserm U876, Institut Fe´de´ratif de Recherche 66, Bordeaux, F-33000 France; 2Universite´ Victor Segalen Bordeaux 2, Bordeaux, F-33000 France
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concentrated viral supernatants by ELISA assay (Innotest HIV p24
INGEN SA, Rungis, France) to determine viral production. For
ESpUROS-EFpGFP and EFpGFP lentiviral supernatant, infectious
titers were determined by transduction of erythroblastic K562 cells
with serial dilutions of viral supernatant. EGFP expression was
quantiﬁed 5 days later by ﬂow cytometric analysis. For ESpUROS
lentiviral supernatant, viral titers were estimated by comparison
of p24 antigen levels of each lentiviral supernatant with a ESpGFP
lentiviral supernatant produced simultaneously. Lentiviral-vector
supernatants were tested for the presence of replication-competent
lentivirus (RCL) as described34 and were found to be free of RCL.
Puriﬁcation, Transduction, and Transplantation
of Murine BM Cells
Donor BALB/cJ CEP mice were injected intraperitoneously with
5-FU (150 mg/kg per mouse). Five days later, nucleated BM cells
were harvested by ﬂushing of femurs and tibiae, puriﬁed by Fi-
coll-PaquePlus gradient separation (AmershamPharmaciaBiotech,
Orsay, France), and sorted for Sca-1þ cells with the MACS Sca-1 kit
(Milteny Biotech, Auburn, CA,USA) (5-FU/Sca-1þ cells). These cells
were prestimulated for 6 hr in RM-B00 medium (MABIO-Interna-
tional Laboratories, Tourcoing, France) containing 10% FCS and
50 mM dNTPs and supplemented with the following cytokines:
rmSCF (100 ng/mL), rhTPO (100 ng/mL), rhFlt3-L (100 ng/mL),
rhIl-6 (10 ng/mL) and rmIl-3 (20 ng/mL). 5-FU/Sca-1þ cells (4 3
105/ml)were transducedwith lentiviral vectors at differentmultiplic-
ity of infections (MOIs) (2–200).
Twenty-four hours after transduction, 5-FU/Sca-1þ cells (7,000
cells in the preliminary experiment and 13,600 to 16,400 cells
for the further experiments) were injected into the tail vein of 6–
10-week-old female CEP mice that had been conditioned with
two doses (25 mg/kg) of Busilvex 24 hr apart. Twenty weeks after
bone-marrow transplantation (BMT), animals were sacriﬁced and
BM cells were harvested. For transplantation of secondary mice,
2–3 3 107 BM cells from primary mice were collected, washed
twice, and injected into the tail vein of 6–10-week-old female
CEP mice that had been conditioned with two doses (25 mg/kg)
of Busilvex 24 hr apart. Neither mortality nor malignant events
were observed in these primary and secondary experiments.
Ter-119þ and Ter-119 Cell Puriﬁcation
BM cells from normal, CEP, and secondary mice were collected by
ﬂushing of tibiae and femurs. Fifteen to twenty million whole BM
cells were collected, washed twice in PBS, and resuspended in PBS
containing 2 mM EDTA with 0.5% HSA. Cells were sorted for Ter-
119þ and Ter-119 fractions with the MACS TER-119 MicroBeads
kit (Miltenyi Biotec, Auburn, CA). More than 90% purity of both
Ter-119þ and Ter-119 fractions was obtained as assessed by ﬂow
cytometric analyses.
PCR Analysis of Proviral Integration
in Colony-Forming Cells
We plated 1500 Sca-1þ cells before graft or 50,000 BM cells from
grafted mice in a methylcellulose-based medium (Methocult GF
M3434, Stem Cell Technologies). Colony-forming cells (CFCs)
were scored on day 10, and 20–60 colonies from each mouse were
picked,washed twicewithPBS, and frozen.Cellswere thendigested
with proteinase K in lysis buffer (10 mmol/l Tris-Cl, pH 8.0, 50
mmol/l KCl, 2.5 mmol/l MgCl2, 0.5% Tween-20, 100 ng/ml pro-
teinase K) at 50C for 1 hr, followed by a 10 min exposure at 95C
to inactivate the proteinase K. The presence of the provirus was114 The American Journal of Human Genetics 82, 113–124, Januarycharacterized by PCR with speciﬁc primers designed in the wood-
chuck posttranscriptional regulatory element (WPRE) sequence
to generate a 220 bp fragment: W1 50-TGCTGTCTCTTTATGAGG
AG-30 as a forward primer andW2 50-GAATTGTCAGTGCCCAACA
G-30 as a reverse primer. Nontransduced colonies were also used as
negative controls.
Flow Cytometric Analysis
Flow cytometric analyses (FACS analyses) of GFP expression in pe-
ripheral blood (PB) or BM were performed on a FACS Calibur (Bec-
ton Dickinson, San Jose, CA). Granulocytes and monocytes in PB
were gated by forward and side scatter and then analyzed for GFP
expression. Purity of 5-FU/Sca-1þ cells was assessed by labeling of
cells with FITC-conjugated anti-Sca-1þ antibody (BD PharMingen,
SanDiego, CA). BM cells were labeled with PE-conjugated anti-Ter-
119 and PE-conjugated anti-GR1 antibodies, (BD PharMingen).
The percentage of GFP-positive lineage cells was calculated as
the percentage of GFP-expressing cells in the total PE-positive
gated regions.
Analysis of Chimerism in Transplanted Mice
The use of males as donors and females as recipients (or recipro-
cally) made it possible to determine chimerism by ﬂuorescence
in situ hybridization (FISH). BM cells were hybridized with a Y
FITC-labeled paint probe for the mouse chromosome Y and a cya-
nin-3-labeled paint probe for the mouse chromosome X (Valbio-
tech, Paris, France), as described.35 A minimum of 300 cells were
examined.
Hematologic Analysis
Blood was collected by puncture of the orbital sinus. Total hemo-
globin, red cell counts, and hematocrit were measured on an Ani-
mal Blood Counter (vetABC, SCIL, Montpellier, France). Analyses
of porphyrin-accumulating cells in PB and BM were performed
with a FACS Calibur (BD Biosciences, Le Pont de Claix, France).
Porphyrin ﬂuorescence was detected in the FL-3 channel. Reticulo-
cytes were labeled with orange thiazol and counted in the FL-1
channel. Half-life was determined with 3 mg of Biotin-X-NHS
(Calbiochem, La Jolla, CA) injected intravenously three times
24 hr apart. RBCs were then detected with a Streptavidin-APC
antibody, (BD PharMingen).
Biochemical Measurements
The quantiﬁcation of the different porphyrins and the
uroporphyrin isomers in urines were done by reverse-phase high-
performance liquid chromatograph (HPLC).36 Uroporphyrinogen
III synthase (UROS) activitywas determinedby an enzyme-coupled
assayasdescribedpreviously.37Oneunitwasdeﬁnedas the amount
of enzyme that formed one nmol of uroporphyrinogen III per hour
at 37C.
Skin Photosensitivity and Morphological Studies
Reversal of skin photosensitivity was assayed with an irradiation
protocol 5months after transplantation.Dorsalmouse skinwas de-
pilated to render mouse skin accessible to irradiation, and the skin
was irradiatedat a total doseof1350kJ/m2 solar-simulated radiation
(SSR)delivered in three sessionswithaSunlightCPSþAtlas (Moussy
le Neuf, France). Skin pictures were taken 5 days after irradiation.
Sheets of dorsal mouse skin were ﬁxed in 4% formalin, dehydrated,
embedded in parafﬁn, cut in 5 mmsections, and stainedwith hema-
toxylin and eosin to visualize the irradiation-induced damage.2008
DNA Analysis
DNA was extracted from BM cells, digested with EcoR1 and Kpn1
restriction enzymes, and subjected to Southern-blot analysis in
order to conﬁrm the presence of unrearranged provirus and de-
termine the integrated vector copy number. A 32P-labeled WPRE
probe was used to hybridize the membrane, and the resulting
bands were visualized and quantitated with a Phosphorimager
(GE Healthcare, Life Sciences).
Quantitative PCR of Proviral DNA
DNA was extracted from 3 3 106 cells with NucleoSpin Tissue kit
(Macherey-Nagel), and real-time PCR was performed on 100 ng of
DNA with Taqman technology (Applied Biosystems). DNA from
nontransduced mice was isolated and ampliﬁed at the same time
to demonstrate the absence of contamination. Samples were
heated to 50C for 2 min and to 95C for 10 min, and then 40 cy-
cles of PCR were performed with 15 s at 95C and 1 min at 60C.
The following sequences were used: 50-ATGGCTTTCATTTTCTCCT
CCTT-30 and 50-CGGGCCACAACTCCTCAT-30 as primers and 50-C
CAACTGGGACGACATG-30 as Taqman probe. Real-time PCR was
performed on b-actin gene for normalization purposes with 50-GA
CCCTGAAGTACCCCATTGAAC-30 and 50-CACGCAGCTCATTGT
AGAAGGT-30 as primers and 50-ATCCTGGTTGCTGTCTC-30 as
Taqman probe. A standard cell line was created by infection of
murine 3T3 cells with MNDpGFP vector at an MOI of 0.5 and
isolation of a 3T3 clone with one proviral insert. DNA from this
cell line was used as a standard for quantiﬁcation by the DCt
method.
Statistical Analysis
Student’s paired t tests were used to compare untreated and treated
mice. Simple linear regression analysis was computed to deter-
mine the association between the percentage of GFPþ RBCs and
GFPþ WBCs. The regression correlation coefﬁcient R2 allowed us
to measure the proportion of variability explained by, or due to,
the regression in the sample of paired data observed. Regression
coefﬁcient models were compared to demonstrate the selective
advantage of corrected cells. All computations were performed
with Excel software and Stata version 7.0 software (Stata, College
Station, TX). All p values were two-sided, and p values less than
0.05 were considered signiﬁcant.
Results
Enzymatic, Metabolic, and Phenotypic Correction
in GT-Treated CEP Mice
Themousemodel of CEP displays erythrodontia, moderate
photosensitivity, hepatosplenomegaly, and hemolytic
anemia.30 Total porphyrins are highly increased in urine
and feces, whereas UROS enzymatic activity is below 1%
of the normal level in the different tissues analyzed. Red
blood cells (RBCs) accumulate large amounts of uropor-
phyrin I and are named ﬂuorocytes because of a character-
istic red ﬂuorescence analyzed by spectroﬂuorimetry or
ﬂow cytometry. These pathological ﬁndings closely mimic
the CEP disease in humans.
The present study tested the feasibility of an ex vivo HSC
gene therapy of the disease with a lentiviral vector. Consid-
ering the predominant erythropoietic expression of theThe Adisease, we decided to use the previously characterized ery-
throid-speciﬁc HS-40 enhancer-ankyrin-1 promoter32,38,39
to drive the expression of the UROS cDNA. We transduced
7,000 to 15,0000 5-FU/Sca1þ BM cells from CEP donor
mice with the erythroid-speciﬁc lentiviral vector ESpUROS
(Figure 1A) and injected them into CEP recipient mice con-
ditioned with two doses (25 mg/kg) of busulfan (Busilvex).
In a preliminary experiment with four mice (MOI of 200),
we obtained 83% CFC integration before grafting, leading
to a fully corrected phenotype with a 200-fold decrease
in total urinary porphyrins, as well as the disappearance
of ﬂuorocytes in peripheral blood. Southern-blot analysis
of genomic DNA from BM at sacriﬁce demonstrated the
presence of a single 2.2 kb band, indicating unrearranged
provirus with a copy number per cell of 17.8 5 1.7 (data
not shown), similar to that measured by qPCR (15.5 5
1.3). However, for a clinical trial, it would be important
to introduce fewer vector copies per cell to reduce the
risk of insertional oncogenesis. We then performed ﬁve
new experiments (20 mice) with lower MOIs (60 or 20
for group I, 20 or 6 for group II, and 2 for group III), and
the results were analyzed as three groups according to
a similar transduction efﬁciency in CFCs before graft:
62.5%–68.2% for group I, 42.9%–45.5% for group II, and
25% for group III (Table 1). Fivemonths after the treatment
in the ﬁrst two groups, there was a complete (group I) or
partial restoration (group II) of enzymatic activity in BM
(Figure 1B). A dramatic decrease in porphyrin accumulation
in urine (Figure 1C; 100–10-fold decrease versus CEP mice)
was obtained, leading to the absence of reddish-colored
urine. FACS analyses showed a rapid disappearance of
ﬂuorocytes as early as one month after transplantation in
these ﬁrst two groups (0.1 5 0.1% and 2.7 5 1.9% for
groups I and II, respectively, versus 32.5 5 2.5% in CEP
mice; Figures 1D and 1E). However, transduction at a very
low level (25% in the CFCs at the time of transduction,
group III) led to a partial metabolic correction (43% de-
crease in urinary porphyrins and 33% decrease in ﬂuoro-
cytes versus CEP mice). Anemia was corrected in groups I
and II with a signiﬁcant increase in hemoglobin concentra-
tion and RBC levels (Table 1) rising to the normal range
(no signiﬁcant difference compared with normal Balb/c
mice). Erythrocyte hemolysis was dramatically reduced as
reﬂected by the reticulocyte counts, the restoration of
RBC half-life, and the considerable reduction in spleno-
megaly (Table 1). However, these three parameters are
not completely normalized for these two groups, because
data differ signiﬁcantly from the wild-type as indicated
by the statistical analysis (Table 1). Only a mild improve-
ment occurred in all hematological parameters in group
III (Table 1), according to the very low level of vector
copy number per cell (0.2 5 0.1, Table 1).
For evaluation of the clinical correction, a photosensitiv-
ity assay was performed 20 weeks after BM transplantation.
Normal mice did not demonstrate any macroscopic or
microscopic skin lesions 5 days after UV exposure, whereas
macroscopic lesions and immune cell inﬁltrates weremerican Journal of Human Genetics 82, 113–124, January 2008 115
Figure 1. Enzymatic, Metabolic, and Phenotypic Correction of Transplanted Mice
(A) Schematic representation of the proviral form of the erythroid-specific SIN lentiviral vector ESpUROS. The following abbreviations are
used: DU3, U3 region deleted of tata box and enhancer sequences; cPPT, central polypurine tract; CTS, central termination sequence;
Dgag, truncated gag region; SA, splice acceptor site; SD, splice donor site; HS40, enhancer of the human a-globin gene; Ankp, ankyrin
promoter of the human ankyrin gene; UROS, cDNA of uroporphyrinogene III synthase; and WPRE, woodchuck posttranscriptional
regulatory element. The WPRE probe for Southern-blot analysis is indicated.
(B) UROS activity in BM cells 20 weeks after transplantation from unmanipulated wild-type BALB/cJ mice (þ/þ), from deficient CEP mice
(CEP), and from the three treated groups of mice (groups I to III).
(C) Level of urinary-porphyrin accumulation in the different groups of mice determined by HPLC.
(D) Representative FACS analysis of the percentage of fluorocytes in peripheral blood from one mouse in each group of controls or treated
mice.
(E) Percentage of fluorocytes monitored over time by FACS in all groups.
Values represent mean5 standard deviation (SD).observed innontransplantedCEPmice. Skinphotosensitiv-
ity completely disappeared inmice treated by gene therapy,
except those in group III, which showed a moderate skin116 The American Journal of Human Genetics 82, 113–124, Januaryphotosensitivity (not shown). Fromthese cohorts of treated
mice, we concluded that our erythroid-speciﬁc lentiviral
vector was relevant for efﬁcient correction of the disease.2008
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Expression
To study the long-term expression of the therapeutic gene
in HSCs, we carried out eight secondary transplants with
BM cells from the eight group I primary recipients. Twenty
weeks after BM transplantation, two secondary mice pre-
sented a very low chimerism (3% and 10.6%, respectively)
and were not included in the analysis. For the six other sec-
ondary mice (90.95 10% chimerism, Table 1), a complete
correction of the diseasewas obtained. Indeed, these highly
engraftedmice did not present any skin lesions, a ﬁnding in
accordance with the restoration of BM UROS activity
(13.5 5 1.9 U/mg of proteins for secondary mice versus
12.15 0.3 for normal control mice in total BM; Figure 2A).
These mice also presented a decrease in the percentage of
ﬂuorocytes in RBCs (Figure 2B) and in urinary porphyrins
(Figure 2C). Finally, hematological parameters were nor-
malized (Table 1, last line). To demonstrate that the correc-
tion occurred with a speciﬁc expression of the transgene in
the erythroid lineage, we isolated Ter-119-positive and
-negative BM cells from normal, CEP, and secondary mice
and measured UROS activity (Figure 2A). Speciﬁc activity
in normal mice was 15-fold higher in erythroid Ter-119þ
compared to Ter-119 cells, thereby conﬁrming the prefer-
ential expression of the mouse endogenous UROS in the
erythropoietic compartment. As expected, UROS activity
was very low in both cellular populations from CEP mice.
In contrast, in secondary mice, UROS activity in Ter-119þ
cells was completely restored (31.25 2.1 U/mg of proteins
forCEPIImiceversus33.650.3U/mgofproteins innormal
mice, Figure 2A). On the other hand, we detected a very low
activity in Ter-119 compared with Ter-119þ cells (p <
0.001), demonstrating the tissue-speciﬁc expression of the
vector in vivo. Therefore, UROS expression limited to the
erythroid lineage was sufﬁcient to correct photosensitivity
in CEP mice.
Selective Advantage of Corrected Cells
Interestingly, in these experiments, the same full correc-
tion was observed for a percentage of CFC integration vary-
ing between 43% and 68% (ﬁrst two groups). These results
suggested a selective advantage of corrected cells due to
a survival advantage of red blood cells and/or a proliferative
advantage of erythroid progenitors. To conﬁrm the pres-
ence of a selective advantage, we performed cell-therapy
experiments with mixed proportions of deﬁcient and
normal cells (Figure 3). With a high proportion of normal
cells (45% and 60%), we obtained a complete metabolic
correction as shown by the low percentage of ﬂuorocytes
(Figure 3A) and the correction of anemia (Figure 3B). Inter-
estingly, a mixture of 30% of normal and 70% of deﬁcient
cells also led to a high correction with a 77% decrease in
ﬂuorocytes. A mixture of 15% of normal and 85% of deﬁ-
cient cells led to a partial correction with a 33% decrease
in ﬂuorocytes.
To investigate the selective advantagemechanism,we de-
signed experiments with two new vectors: One is a markerhe American Journal of Human Genetics 82, 113–124, January 2008 117
Figure 2. Erythroid-Specific Expression in Secondary Mice
(A) UROS activity in whole BM and in Ter-119þ- and Ter-119-sorted BM cells 20 weeks after transplantation from wild-type (þ/þ),
CEP-deficient mice (CEP), and secondary recipients (CEPII).
(B) Percentage of fluorocytes monitored over time by FACS from all groups.
(C) Level of urinary-porphyrin accumulation in different groups of mice determined by HPLC.
Values represent mean5 SD.GFP vector under the control of the ubiquitous elongation
factor 1 alpha (EF1a) promoter, named EFpGFP; the other is
a bipromoter vector expressing both theUROS cDNAdriven
by the erythroid-speciﬁc promoter and the GFP under the
control of the EF1a promoter, named ESpUROS-EFpGFP
(Figure 4A). Using the simplemarker vector EFpGFP,weﬁrst
studied the level of GFP expression in the erythroid and
nonerythroid compartments at different MOIs (Figure 4B).
Analysis of CEP mice at 4 and 12 weeks showed a lower
expression of GFP in RBCs compared to white blood cells
(WBCs), with a ratio of 0.36 (slope of the linear regression
curve). This different level of expression was not due to
the disease itself because a similar ratio (0.42–0.48) was
foundwith normalmice. Rather, it was due to a characteris-
tic of the promoter, which is weaker in RBCs compared to
WBCs. In contrast, experiments performed with the thera-
peutic vector ESpUROS-EFpGFP showed a higher GFP
expression in RBCs with an inverted ratio (2.29–2.34, p <
0.001) (Figure 4B). This result is due to the presence of the
therapeutic gene, with a survival advantage of genetically
corrected cells compared to the deﬁcient red blood cells.
As expected, Figure 4C shows the inverse correlation
between the percentage of ﬂuorocytes (corresponding to
noncorrected cells) and the percentage of GFP-positive
RBCs.
For determining whether a selective advantage occurred
in the bone marrow at an early stage of the erythropoietic
differentiation, cells were gated on Ter-119 expression
(Figure 5A) and three different groups were distinguished
according to their side scatter (SSC) and forward scatter
(FSC) proﬁles: (III) early normoblasts, (II) intermediate nor-
moblasts, and (I) RBCs (Figure 5A). The percentage of GFP-
positive cells in these three groups was compared with that
in the myeloid compartment (Gr-1-positive cells). When
the simple EFpGFP marker vector in normal and deﬁcient118 The American Journal of Human Genetics 82, 113–124, Januarymice was used, GFP expression was lower in the different
populations of the erythroid compartment compared to
Gr-1-positive cells (Figure 5B). This was observed previ-
ously in peripheral blood when we compared the percent-
ages of GFP-positive cells between RBCs and WBCs
(Figure 4B). This is a characteristic of the EF1a promoter
given that the use of another constitutive promoter
(MNDp) led to an identical level of expression in all line-
ages (Figure 5B, left part). Using the therapeutic
ESpUROS-EFpGFP vector, we observed a 2-fold increase
in GFP expression in early normoblasts compared to the
use of the simple vector (EFpGFP), suggesting that amoder-
ate proliferative advantage exists at an early stage of ery-
throid differentiation. In addition, a 5-fold increase in
the percentage of GFP-expressing cells was observed in
peripheral RBCs between EFpGFP-treated and ESpUROS-
EFpGFP-treated mice. This result is in accordance with
the results of Figure 4B, demonstrating the survival advan-
tage of peripheral corrected cells.
Level of Transduction Necessary to Obtain a Complete
Correction of CEP Mice
To assess the level of transduction necessary for ametabolic
correction, we analyzed the percentage of GFPþ WBCs
(which reﬂects the initial percentage of HSC transduction)
versus the percentage of ﬂuorocytes at 4 and 12 weeks. The
population of mice corresponding to a percentage of trans-
duction R 40% presented a total metabolic and pheno-
typic correction (Figure 6). These results are in agreement
with the initial experiments obtained with the ﬁrst two
groups of mice, which presented a complete or near-com-
plete metabolic correction (see Table 1). In contrast, mice
grafted with a percentage of genetically modiﬁed cells %
10% had neither metabolic nor phenotypic correction:
They showed a percentage of ﬂuorocytes between 20%2008
Figure 3. Cell-Therapy Experiments
(A) Percentage of fluorocytes monitored over time by FACS in the CEP-deficient mice (CEP) and mice treated by BM transplantation: BMT
15% (15% of normal cells mixed with 85% of deficient cells), BMT 30%, BMT 45% and BMT 60%. (B) Hematological parameters (RBCs,
hemoglobin, hematocrit and reticulocyte counts) were analyzed for the different groups of mice 24 weeks after transplantation.and 40% and remained photosensitive (Figure 6). Experi-
ments performed with a percentage of transduction be-
tween 10% and 40% led to a partial correction (ﬂuorocytes
between 5% and 15%, mild photosensitivity, Figure 6 and
group III in Table 1).
Discussion
The evaluation of the efﬁcacy and safety of lentiviral-medi-
ated gene therapy for genetic diseases requires an animal
model. We have now developed a knock-in mouse model
of CEP (Urosmut248) that reproduces the missense mutation
(pP248Q) observed in the human disease.30 Homozygous
urosmut248/mut248 mice presented with skin photosensitiv-
ity and hemolytic anemia as observed in the disease in
humans. Recently, Bishop et al.40 reported a new viable
homozygous knock-in mouse model of CEP in which the
C73R/V99A mutations are responsible for a milder pheno-
type. Our new model allowed us to test an ex vivo gene
therapy consisting in the autograft of genetically modiﬁed
stem cells. By using a lentiviral vector to deliver an
erythroid-speciﬁc expression cassette for human UROS
cDNA, we achieved persistent and long-term correction
of porphyrinuria and hemolytic anemia and a complete
cure of the CEP phenotype, i.e., photosensitivity, in this
new model. Correction of the disease in secondary mice
(in which engrafted cells are provided by the ﬁrst trans-
planted mice) clearly demonstrates that the gene correc-
tion occurs at the stem cell level. This correction was efﬁ-
cient at a moderate transduction level of HSCs in theThe Aabsence of a selection system. Because of shortened red
cell survival in our disease, gene-corrected erythroid cells
are likely to be preferentially ampliﬁed. Here we clearly
demonstrate a survival advantage of corrected red blood
cells with 5-fold ampliﬁcation and restoration of their
half-life. A signiﬁcant ampliﬁcation of the erythroid
lineage derived from the genetically normal HSCs was
also observed in a murine model of b-thalassemia.41,42
These ﬁndings constitute a signiﬁcant advance over other
hematologic diseases requiring a selection system or a high
transduction level of HSCs for a complete cure. Our results
contrast with the data obtained with another porphyria,
erythropoietic protoporphyria (EPP, [MIM 177000]), which
is characterized by an accumulation of protoporphyrin in
RBCs and the absence of hemolytic anemia. During the
course of gene therapy of this murine model, no selective
advantage was found.33,43,44 Other studies will be needed
to test whether the survival advantage is sufﬁcient to allow
a milder conditioning regimen, as is the case for gene ther-
apy in other genetic diseases. For example, Aiuti et al. suc-
cessfully transplanted autologous ADA-transduced stem
cells into two children with ADA-SCID after nonmyeloa-
blative conditioning with busulfan (4 mg/kg).22 However,
if we consider the necessity to use lowmultiplicity of infec-
tion in order to avoid multiple integration events, the
transduction efﬁciency will not reach more than 40%–
60%. In this paper, we demonstrate that a minimum of
40% corrected cells is required to obtain a complete meta-
bolic and phenotypic correction, suggesting that a full
chimerism is likely to be necessary. In the case of partial
conditioning, chimerism can be reinforced by conferringmerican Journal of Human Genetics 82, 113–124, January 2008 119
Figure 4. Selective Advantage of Corrected Erythropoietic Cells
(A) Schematic representation of the proviral form of the three SIN lentiviral vectors. The first two are constitutive vectors expressing GFP
from the LTR-derived MND or the human cellular EF1a promoter. The third is a bipromoter vector coexpressing UROS cDNA from the
erythroid HS40/Ank promoter and GFP from the EF1a promoter.
(B) GFP expression in red blood cells (RBCs) and white blood cells (WBCs), 4 and 12 weeks after BM transplantation. The dots correspond
to individual CEP mice transplanted with HSCs transduced at five different MOIs (2, 6, 20, 60, and 80) either with the EFpGFP (B) or with
the ESpUROS-EFpGFP (A) vector. Arrows emphasize the difference in the slopes of the curves obtained with the two vectors, reflecting
the survival advantage of corrected RBCs.
(C) Relation between the percentage of fluorocytes and the percentage of GFPþ RBCs at 4 and 12 weeks. CEP mice were transplanted with
HSCs transduced with the therapeutic ESpUROS-EFpGFP vector.a selective advantage to transduced hematopietic stem
cells. It would be interesting to evaluate a lentiviral vector
that coexpresses UROS and a selective gene such as the
O6-methylguanine-DNA-methyltransferase (MGMT),31,45
chemical inducers of dimerization,46 or the truncated
Epo receptor.47
The recent reports of insertional leukemogenesis in 4 of
11 patients who were treated by gene therapy for SCID-
X148 due to activation of the LMO2 gene by the pro-
moter of the integrated provirus underscore the need for
safer vectors that would be lineage speciﬁc and have en-
hancer-blocking effects. In the present study, the use of a
cellular promoter instead of a retroviral promoter reduced
the level of gene deregulation in the neighborhood of120 The American Journal of Human Genetics 82, 113–124, Januaryproviral integration.49 In addition, the use of erythroid-
speciﬁc lentiviral vectors would therefore conﬁne the risk
of oncogene activation to a single lineage. The probability
of promoter transactivation by vector-encoded enhancers
could be further reduced by the incorporation into the
vectors of insulators such as cHS4.50–52
The clinical course of CEP disease is rapidly devastating
because of a rapid extension of cutaneous impairment
including loss of digits, eyelids, nostrils, and ears. Anemia
due to erythrocyte hemolysis can be life threatening if the
marrow cannot compensate, and severely affected patients
are transfusion dependent. In the past, death often occurs
before the age of 40 as a result of multiple organ failure. In
the most severe forms, the disease develops in utero,2008
Figure 5. Selective Advantage of Corrected Cells of the Erythroid Lineage
(A) Representative FACS analysis of BM cells and peripheral RBCs from each group of mice. BM cells were analyzed for Ter-119 expression,
and three different groups were differentiated by their SSC and FSC profiles (upper left part): (I) RBCs, (II) intermediate normoblasts, and
(III) early normoblasts. BM cells were also analyzed for Gr-1 expression (upper middle part). GFP expression was then analyzed in each
population of erythroid (Ter-119) and myeloid (Gr-1) BM cells and in peripheral RBCs (right part).
(B) Ratio of the percentage of GFP expression between the different populations of erythropoietic cells and Gr-1-positive cells. *p< 0.01
versus MNDpGFP vector in normal mice; **p< 0.001 versus EFpGFP vector in normal and CEP mice; ***p < 0.001 versus ESpUROS-EFpGFP
vector in the different populations of erythropoietic cells of CEP mice.
Values for (B) represent mean5 SD.The American Journal of Human Genetics 82, 113–124, January 2008 121
Figure 6. Level of Transduction Neces-
sary to Obtain a Complete Correction of
the Phenotype
CEP mice were transplanted with HSCs
transduced with the therapeutic ESpUROS-
EFpGFP vector (same experiments as in
Figure 4C), and the percentages of fluoro-
cytes and GFPþ WBCs were determined for
each mouse at 4 and 12 weeks. In the right
part, skin photosensitivity was assayed 20
weeks after transplantation: (A), mice
with severe skin photosensitivity; ( ),
mice with mild photosensitivity; and (>)
mice without any macroscopic or micro-
scopic lesions.leading to premature abortion or death in the neonatal
period.8,9 BM transplantation, which is proposed in severe
forms of the disease diagnosed in the ﬁrst years of life, has
proven curative in patients with CEP: 11 cases have been
reported.10–19 However, this treatment is limited by the
need for an HLA-identical donor and is associated with
a signiﬁcant risk of morbidity and mortality. In the case
of a gene-therapy clinical trial, the survival advantage of
corrected cells is likely to be dependent on the severity of
hemolysis. This point can be a problem for patients with
severe photosensitivity, which may in itself justify gene
therapy, but with absence of (or well-compensated) hemo-
lysis. A clinical trial will concern in the ﬁrst place severe
cases with hemolytic anemia. Splenomegaly as a conse-
quence of hemolytic anemia is a nearly obligate sign in
CEP and sometimes results in leukopenia and thrombocy-
topenia (hypersplenism). Splenectomy may minimize the
hemolytic anemia and reduce transfusion requirement in
some patients, but it is not always beneﬁcial.8 It will be
interesting to test the effect of splenectomy on the hemo-
lytic anemia in our CEP mouse model.
The success of BM transplantation in alleviating the
severe manifestations of the disease provides the rationale
for hematopoietic stem cell (HSC) gene therapy. Previous
experiments performed into Epstein-Barr-virus-trans-
formed B cell lines37 showed the absence of transcellular
complementation between transduced and nontrans-
duced cells. This is not surprising because uroporphyrin
I, which is the main formed compound in the absence of
the enzyme UROS, corresponds to a metabolic dead end.
We very efﬁciently transduced humanCD34þ cells isolated
from mobilized peripheral blood (mPB).53 The experi-
ments performed in vitro with lentiviral vectors demon-
strated that the level of enzymatic correction obtained by
gene transfer was sufﬁcient to allow total metabolic correc-
tion of the cells in the short and long term.54 The evalua-
tion of UROS gene-transfer efﬁciency, expression, and
safety in an immunodeﬁcient mouse model should rein-
force these preclinical studies.
In conclusion, the cure of the mouse model of CEP
supports the proof of concept of clinical testing of gene
therapy in this severe disease. The survival advantage of122 The American Journal of Human Genetics 82, 113–124, Januarycorrected red blood cells is a major argument for a thera-
peutic beneﬁt in human because not all the stem cells
need to be corrected.
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